<< Thomson Reuters includes coverage in 15 more languages for Micromedex CareNotes patient education system | 'Neural inertia' may explain brain's resistance to changes in consciousness >>
Read in | English | Filipino | Finnish | Русский

Stallergenes first half-year 2010 EBITDA increases by 48% to EUR 35.6 million

Published on August 27, 2010 at 7:19 AM · No Comments

- First Half-Year 2010 RESULTS - Excellent 1st Half-Year 2010 Performance by Stallergenes - Growth in France and Internationally +13% - Very Strong net Profit Growth +51% - Free Cash Flow Growth +90%

The Board of Directors' approved the 2010 half-year financial statements at its meeting of 25 August 2010, chaired by Albert SAPORTA:

Sales growth and financial position

Sales grew by 13% in the first half-year. This significant increase reflected the continuing advancement of sublingual treatments, in particular buoyant Oralair(R) sales in Germany.

Under the combined effect of this growth and the temporary reduction in R&D expenditure, a significant increase in earnings was achieved in the 1st half-year 2010. Overall, the profit before R&D rose moderately in relative value and represented 38.6% of sales, compared to 38.2% in the 1st half-year 2009. R&D expenditure fell very significantly by 22% in the first half-year and went from 21.8% of sales in 2009 to 15.0% this year. This decline was due to a timing difference between the end of the clinical studies in progress (and particularly the Oralair(R) study in the US) and the start of new studies. Operating profit rose by 51% to EUR 29.5 million. The net diluted earnings per share grew by 49% to EUR 1.50.

EBITDA grew by 48% to EUR 35.6 million. Investments temporarily fell by 26% over the half-year to EUR 6.9 million. As a result, and also due to stable working capital requirements, free cash flow recorded a significant 90% increase to EUR 27.6 million.

At 30 June, net cash resources grew from EUR 1.3 million in 2009 to EUR 25.0 million in 2010.

The half-year financial report can be downloaded from the website: http://www.stallergenes.com

At its meeting of 25 August 2010, the Board of Directors authorised the implementation of the share buyback programme approved by the Annual General Meeting of 28 May 2010, which will not exceed EUR 10 million and will more particularly be used to cover stock options and performance-based share payments.

Significant recent transactions and events

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading